Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis Bioresearch Inks Canadian Distribution Deal

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cellectis Bioresearch, a subsidiary of French firm Cellectis, said Tuesday that Cedarlane will distribute Cellectis Bioresearch's kits in Canada.

Cellectis said that it will be responsible for the design and production of targeted integration kits from its Cellular Genome Positioning System (cGPS) and cGPS Custom lines. Cedarlane will distribute the kits to research labs in Canada, providing Cellectis Bioresearch with a "foothold in the North American research market," the French firm said.

"Targeted integration using meganucleases – the basis of Cellectis bioresearch's kits – makes the generation of stable cell lines fast and effortless," Luc Selig, VP of sales and marketing for Cellectis Bioresearch, said in a statement. "This agreement will help us to rapidly expand the network of users for our kits."

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.